Capsule Summaries

Share

Program Content

Activities

SAVANNAH
SAVANNAH: Phase II Trial of Savolitinib + Osimertinib for Advanced EGFRm NSCLC With MET Amplification or Overexpression After Progressing on Osimertinib
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 02, 2025

Expires: October 01, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc